Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.

Date publication

janvier 2015

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre

Tous les auteurs :
About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26670100

Résumé

Human genetic factors influence the outcome of pegylated interferon and ribavirin hepatitis C therapy. We explored the role of IL28B, APOH and ITPA SNPs on the outcomes of triple therapy including telaprevir or boceprevir in patients with compensated cirrhosis chronically infected with HCV-1.

Mots clés

Anemia, complications, Drug Therapy, Combination, Hemoglobins, metabolism, Hepacivirus, physiology, Hepatitis C, Chronic, complications, Humans, Interleukins, genetics, Liver Cirrhosis, complications, Oligopeptides, adverse effects, Polymorphism, Single Nucleotide, genetics, Proline, adverse effects, Pyrophosphatases, genetics, Treatment Outcome, beta 2-Glycoprotein I, genetics

Référence

PLoS ONE. 2015 ;10(12):e0145105